Pipeline

We are leveraging our proprietary kinase switch control inhibitor platform to develop a pipeline of highly selective, potent small molecule drug candidates that directly inhibit activation of kinases implicated in the growth and spread of cancers. We currently retain global development and commercialization rights to our drug candidates.

Tumor-Targeted Programs and Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Global Rights
DCC-2618 KIT & PDGFRα

GIST

Deciphera
PDGFRα

GBM & Glioma

Deciphera
KIT (D816V)

Advanced Systemic Mastocytosis

Deciphera
KIT & PDGFRα

Other Cancers

Deciphera
Immunokinase Programs and Indications
Rebastinib TIE2

Breast Cancer + Chemotherapy

Deciphera
TIE2

Checkpoint Inhibitor Combination

Deciphera
DCC-3014 CSF1R

Solid Tumors & Hematological Malignancies

Deciphera
CSF1R

Checkpoint Inhibitor Combination

Deciphera
Tumor-Targeted Programs and Indications
Phase Global Rights
DCC-2618
KIT & PDGFRα

GIST

Phase 1 Deciphera
PDGFRα

GBM & Glioma

Phase 1 Deciphera
KIT (D816V)

Advanced Systemic Mastocytosis

Phase 1 Deciphera
KIT & PDGFRα

Other Cancers

Phase 1 Deciphera
Immunokinase Programs and Indications
Phase Global Rights
Rebastinib
TIE2

Breast Cancer + Chemotherapy

Phase 1 Deciphera
TIE2

Checkpoint Inhibitor Combination

Phase 1 Deciphera
DCC-3014
CSF1R

Solid Tumors & Hematological Malignancies

Phase 1 Deciphera
CSF1R

Checkpoint Inhibitor Combination

Phase 1 Deciphera